PTC Therapeutics (PTCT) News Today $49.55 -0.40 (-0.80%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period PTC Therapeutics' (PTCT) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and set a $65.00 price target on shares of PTC Therapeutics in a research report on Tuesday.April 24 at 10:45 AM | marketbeat.comPTC Therapeutics to Participate at Upcoming Investor ConferencesApril 24 at 8:00 AM | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Short Interest UpdatePTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,420,000 shares, a growth of 26.0% from the March 15th total of 4,300,000 shares. Approximately 7.4% of the shares of the company are short sold. Based on an average daily volume of 871,300 shares, the days-to-cover ratio is currently 6.2 days.April 22 at 8:31 AM | marketbeat.comRBC sees Makary interview as potentially positive for biotech stocksApril 22 at 3:20 AM | markets.businessinsider.comAlpha DNA Investment Management LLC Buys Shares of 10,258 PTC Therapeutics, Inc. (NASDAQ:PTCT)Alpha DNA Investment Management LLC purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,258 shares of the biopharmaceutical company's stock, valued atApril 21 at 5:45 AM | marketbeat.comXTX Topco Ltd Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)XTX Topco Ltd bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 13,223 shares of the biopharmaceutical company's stock, valued at approximately $597,000. Several other hedge funApril 21 at 4:50 AM | marketbeat.comJump Financial LLC Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Jump Financial LLC purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 62,809 shares of the biopharmaceutical company's stock, valued at approximately $2,April 20, 2025 | marketbeat.comWalleye Capital LLC Invests $4.97 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Walleye Capital LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 110,004 shares of the biopharmaceutical company's stApril 19, 2025 | marketbeat.comPTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on ThursdayPTC Therapeutics (NASDAQ:PTCT) will be releasing earnings before the market opens on Thursday, April 24, Financial Modeling Prep reports.April 19, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Up 6.8% - Time to Buy?PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.8% - What's Next?April 17, 2025 | marketbeat.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial ResultsApril 17, 2025 | prnewswire.comRussell Investments Group Ltd. Reduces Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Russell Investments Group Ltd. reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 26.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 170,697 shares of the biopharmaceutiApril 15, 2025 | marketbeat.comFederated Hermes Inc. Invests $2.16 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Federated Hermes Inc. bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 47,828 shares of the biopharmaceutiApril 15, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 114,900 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Renaissance Technologies LLC raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 653,100 shares of the biopharmaceutical company's stock after buyinApril 14, 2025 | marketbeat.comAlliancebernstein L.P. Increases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Alliancebernstein L.P. raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 62.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 361,644 shares of the biopharmaceutical compApril 11, 2025 | marketbeat.comADAR1 Capital Management LLC Raises Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)ADAR1 Capital Management LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 140.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,023 shares of the biopharmaceutical compApril 9, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, fourApril 9, 2025 | marketbeat.comAmerican Century Companies Inc. Buys 24,090 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)American Century Companies Inc. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 66.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,150 shares of the biopharmaceuticalApril 9, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (PTCT) and Qiagen (QGEN)April 7, 2025 | markets.businessinsider.comHeadlands Technologies LLC Increases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Headlands Technologies LLC boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 843.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,228 shares of the biopharmaceutical company's stApril 7, 2025 | marketbeat.comLee Scott Golden Sells 897 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 897 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $46.95, for a total transaction of $42,114.15. Following the completion of the sale, the executive vice president now directly owns 75,997 shares of the company's stock, valued at approximately $3,568,059.15. This trade represents a 1.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 6, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 897 SharesApril 5, 2025 | insidertrades.comWellington Management Group LLP Sells 3,105,676 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Wellington Management Group LLP lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,787,123 shares of the biopharApril 4, 2025 | marketbeat.comVanguard Group Inc. Buys 53,688 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Vanguard Group Inc. lifted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,178,822 shares of the biopharApril 4, 2025 | marketbeat.comTrexquant Investment LP Purchases 95,418 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Trexquant Investment LP raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 43.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 313,417 shares of the biopharmaceutical company's stock after purchApril 3, 2025 | marketbeat.comKLP Kapitalforvaltning AS Invests $646,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)KLP Kapitalforvaltning AS bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,300 shares of the biopharmaceutical company's stock, valuedApril 3, 2025 | marketbeat.comThrivent Financial for Lutherans Sells 18,759 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Thrivent Financial for Lutherans trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 48.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,339 shares of the bioApril 3, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst DowngradePTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% After Analyst DowngradeApril 1, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceJPMorgan Chase & Co. reduced their target price on shares of PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday.April 1, 2025 | marketbeat.comPictet Asset Management Holding SA Acquires 381,319 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Pictet Asset Management Holding SA boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 107.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 736,388 shares of the biopApril 1, 2025 | marketbeat.com48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Raymond James Financial Inc.Raymond James Financial Inc. acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 48,728 shares of the biopharmaceutiMarch 31, 2025 | marketbeat.comPTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On TranslarnaMarch 30, 2025 | nasdaq.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2025 | prnewswire.comPTC Therapeutics says European Commission will remove muscle disorder drugMarch 28, 2025 | reuters.comPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in EuropeMarch 28, 2025 | prnewswire.comNatixis Advisors LLC Makes New $544,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Natixis Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,060 shares of the biopharmaceMarch 28, 2025 | marketbeat.comFirst Week of May 16th Options Trading For PTC TherapeuticsMarch 26, 2025 | nasdaq.comCibc World Markets Corp Invests $322,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)Cibc World Markets Corp purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,127 shares of the biopharmaceutical company's stock, valued at approximately $322,00March 25, 2025 | marketbeat.comProficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Proficio Capital Partners LLC purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 16,792 shares of the biopharmaceutical companyMarch 23, 2025 | marketbeat.comSector Gamma AS Takes $2.95 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Sector Gamma AS purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 65,250 shares of the biopharmaceutical company's stMarch 22, 2025 | marketbeat.comPTC Therapeutics' New Data Shows Meaningful Benefit Of Sepiapterin In Phenylketonuria PatientsMarch 22, 2025 | nasdaq.comPTC Therapeutics (NASDAQ:PTCT) Sets New 12-Month High - Here's What HappenedPTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week High - Here's What HappenedMarch 21, 2025 | marketbeat.comPTC Therapeutics presents new data from Phase 3 APHENITY trialMarch 21, 2025 | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 23,632 shares of the biopharmaceutical company's stock after selMarch 21, 2025 | marketbeat.comAlphaQuest LLC Sells 21,277 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)AlphaQuest LLC decreased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 95.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,082 shares of the biopharmaceutical company's stock aftMarch 21, 2025 | marketbeat.comPTC Therapeutics Presents New Sepiapterin Data from Ongoing StudiesMarch 20, 2025 | prnewswire.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells 5,000 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Stephanie Okey sold 5,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now directly owns 8,867 shares in the company, valued at approximately $478,818. This represents a 36.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 18, 2025 | marketbeat.comStephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockMarch 18, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. reduced its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 685,709 shares of the biopMarch 17, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 15,521 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $53.30, for a total transaction of $827,269.30. Following the completion of the sale, the vice president now owns 103,901 shares in the company, valued at $5,537,923.30. The trade was a 13.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.March 15, 2025 | marketbeat.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.800.72▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼127▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News ITCI News GMAB News RDY News ASND News MRNA News VTRS News QGEN News ROIV News LNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts